Merck, J&J CEOs agree to testify in Senate hearing on drug prices

US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and … Read more

Treasury yields fractionally higher ahead of key data releases

U.S. Treasury yields nudged slightly higher on Tuesday morning, as market participants await the release of key economic data points later in the week. Near 2:25 a.m. ET, the yield on the benchmark 10-year Treasury note was around 1.7 basis points higher at 4.1109% while the yield on the 30-year Treasury bond was up just … Read more

Moderna Covid vaccine sales plunge in 2023, but meet company forecast

Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s forecast for the year, even as sales plummeted from the … Read more

Jim Cramer reviews the worst performers on the Nasdaq-100 in 2023

CNBC’s Jim Cramer on Thursday gave his take on the worst performers in the Nasdaq-100 in 2023. Cramer compared each company’s closing price in 2022 to the end of 2023, noting the biggest losers. The list included healthcare companies as well as several utilities outfits. “You’ve heard of the Dogs of the Dow? Well, now … Read more

A disappointing start to the year

Traders work on the floor of the New York Stock Exchange (NYSE) on the first trading day of 2024 on January 02, 2024 in New York City.  Spencer Platt | Getty Images This report is from today’s CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything … Read more

Moderna stock jumps after Oppenheimer upgrade on pipeline potential

Artur Widak | Nurphoto | Getty Images Shares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock has … Read more

Health sector themes to watch in 2024

An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and … Read more

Jim Cramer’s top 10 things to watch in the stock market Thursday

My top 10 things to watch Thursday, Dec. 14 1. U.S. stocks are higher in premarket trading Thursday, with S & P 500 futures up 0.46%. Equities rallied Wednesday after the Federal Reserve held interest rates steady, while indicating it would cut rates three times in 2024 — a decision more dovish than I expected. … Read more

Moderna, Merck cancer vaccine reduces risk of skin cancer return

An exterior view of Moderna’s clinical manufacturing facility.  David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage … Read more